Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM ESTCompany ParticipantsSteve Chapman - CEO & ...

Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...

Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor Olema Pharmaceuticals Inc. Made public were positive phase III data from ...

According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

FDA approves Poherdy, the first interchangeable biosimilar for Perjeta, enhancing competition in HER2-positive breast cancer ...

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

European shares fell on Tuesday, with those in Germany near a five-month low as a broad risk-off mood gripped global markets, ...

OLMA stock surged 197% after Roche’s SERD breakthrough, signaling investor conviction in the future of ER-positive breast ...

(OLMA) more than doubled Tuesday morning on the heels of Roche announcing positive results from its late-stage trial in ...